Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C
This article was originally published in The Pink Sheet Daily
Executive Summary
BI's '355 has impressive response rates in early studies, but jaundice is a concern.
You may also be interested in...
Boehringer’s Next Gen Protease Inhibitor Potent In Tough-to-Treat Hep C Patients
Phase II data presented at the American Association for the Study of Liver Disease meeting on BI 201335 support efficacy in hard to treat genetic subtypes and with shorter treatment periods.
Vertex's Telaprevir Works In Twice Daily Dose; Response-Guided Therapy Cuts Down Drop-Outs
Is it a trick or a treat? AASLD lifts embargo on all annual meeting data at Halloween press conference.
INFORM-1 Data Show Potential Efficacy And Safety Of Roche HCV Combo
Combination therapy with two experimental, oral, direct-acting antivirals in treatment-naïve hepatitis C patients showed significant viral-load reductions and a clean safety profile, Roche and its biotech partners on the two drugs announced April 25 during the European Association for the Study of the Liver conference in Copenhagen, Denmark